Clinicopathological features in anterior visual pathway in neuromyelitis optica

Annals of Neurology

Volumn 79, Issue 4, 2016, Pages 605-624

  Hokari, Mariko ^a   Yokoseki, Akiko ^a   Arakawa, Musashi ^a   Saji, Etsuji ^a   Yanagawa, Kaori ^a   Yanagimura, Fumihiro ^a   Toyoshima, Yasuko ^a   Okamoto, Kouichirou ^a   Ueki, Satoshi ^a   Hatase, Tetsuhisa ^a   Ohashi, Riuko ^b   Fukuchi, Takeo ^a   Akazawa, Kohei ^b   Yamada, Mitsunori ^c   Kakita, Akiyoshi ^a   Takahashi, Hitoshi ^a   Nishizawa, Masatoyo ^a   Kawachi, Izumi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4;

ANTERIOR VISUAL PATHWAY; ARTICLE; ASTROCYTE; CELL DAMAGE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; FEMALE; FOLLOW UP; GLIA; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MENINGITIS; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; MUELLER CELL; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE CELL; NERVE DEGENERATION; NEUROIMAGING; NEUROMYELITIS OPTICA SPECTRUM DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OPTIC CHIASM; OPTIC NERVE; OPTIC NEURITIS; OPTIC TRACT; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR POTENTIAL; RETINA; RETINA NERVE CELL; RETINAL NERVE FIBER LAYER; RETROGRADE DEGENERATION; VISION; VISUAL IMPAIRMENT; VISUAL SYSTEM; WALLERIAN DEGENERATION; ADULT; AXON; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; VISUAL DISORDER;

ADULT; AQUAPORIN 4; ASTROCYTES; AXONS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; OPTIC NEURITIS; VISION DISORDERS; VISUAL PATHWAYS;

EID: 84958721583     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24608     Document Type: Article

References (50)

1. Wingerchuk DM, Lennon VA, Pittock SJ, et al., Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
3. Lennon VA, Kryzer TJ, Pittock SJ, et al., IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
4. Merle H, Olindo S, Bonnan M, et al., Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114: 810-815.
5. Wingerchuk DM, Weinshenker BG,. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853.
6. de Seze J, Blanc F, Jeanjean L, et al., Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008; 65: 920-923.
7. Naismith RT, Tutlam NT, Xu J, et al., Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72: 1077-1082.
8. Verkman AS, Ruiz-Ederra J, Levin MH,. Functions of aquaporins in the eye. Prog Retin Eye Res 2008; 27: 420-433.
9. Yanagawa K, Kawachi I, Toyoshima Y, et al., Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009; 73: 1628-1637.
10. Tanaka K, Tani T, Tanaka M, et al., Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler 2007; 13: 850-855.
11. Polman CH, Reingold SC, Banwell B, et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
12. Saji E, Arakawa M, Yanagawa K, et al., Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 2013; 73: 65-76.
13. Liu G, Amin S, Okuhama NN, et al., A quantitative evaluation of peroxidase inhibitors for tyramide signal amplification mediated cytochemistry and histochemistry. Histochem Cell Biol 2006; 126: 283-291.
14. Lassmann H,. Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol 2011; 37: 698-710.
15. Perego C, Fumagalli S, De Simoni MG,. Three-dimensional confocal analysis of microglia/macrophage markers of polarization in experimental brain injury. J Vis Exp 2013 (79).
16. Parikh RS, Parikh SR, Sekhar GC, et al., Normal age-related decay of retinal nerve fiber layer thickness. Ophthalmology 2007; 114: 921-926.
17. Kupersmith MJ, Alban T, Zeiffer B, Lefton D,. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 2002; 125 (pt 4): 812-822.
18. Keltner JL, Johnson CA, Cello KE, et al., Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol 2010; 128: 330-337.
19. Purvin V, Kawasaki A, Jacobson DM,. Optic perineuritis: clinical and radiographic features. Arch Ophthalmol 2001; 119: 1299-1306.
20. Hickman SJ, Toosy AT, Jones SJ, et al., A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004; 127 (pt 11): 2498-2505.
21. Roemer SF, Parisi JE, Lennon VA, et al., Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130 (pt 5): 1194-1205.
22. Archer SL,. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N Engl J Med 2013; 369: 2236-2251.
23. Kang JS, Tian JH, Pan PY, et al., Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell 2008; 132: 137-148.
24. Schattling B, Steinbach K, Thies E, et al., TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2012; 18: 1805-1811.
25. Pannicke T, Wurm A, Iandiev I, et al., Deletion of aquaporin-4 renders retinal glial cells more susceptible to osmotic stress. J Neurosci Res 2010; 88: 2877-2888.
26. Yuan S, Zhang W, Ding J, et al., Increased sensitivity to retinal light damage in aquaporin-4 knockout mice. Exp Eye Res 2009; 89: 119-122.
27. Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, et al., Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 2001; 42: 975-982.
28. Levin MH, Bennett JL, Verkman AS,. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res 2013; 36: 159-171.
29. Killer HE, Jaggi GP, Flammer J, et al., Cerebrospinal fluid dynamics between the intracranial and the subarachnoid space of the optic nerve. Is it always bidirectional? Brain 2007; 130 (pt 2): 514-520.
30. Hofman P, Hoyng P, vanderWerf F, et al., Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest Ophthalmol Vis Sci 2001; 42: 895-901.
31. Agrawal S, Anderson P, Durbeej M, et al., Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006; 203: 1007-1019.
32. Bjartmar C, Kidd G, Mork S, et al., Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
33. Mahad DH, Trapp BD, Lassmann H,. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14: 183-193.
34. Dziedzic T, Metz I, Dallenga T, et al., Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol 2010; 20: 976-985.
35. Nikic I, Merkler D, Sorbara C, et al., A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-499.
36. Mahad DJ, Ziabreva I, Campbell G, et al., Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132 (pt 5): 1161-1174.
37. Osterloh JM, Yang J, Rooney TM, et al., dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 2012; 337: 481-484.
38. Conforti L, Gilley J, Coleman MP,. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 2014; 15: 394-409.
39. Kaneko S, Wang J, Kaneko M, et al., Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci 2006; 26: 9794-9804.
40. Hinson SR, Roemer SF, Lucchinetti CF, et al., Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205: 2473-2481.
41. Geis C, Ritter C, Ruschil C, et al., The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Exp Neurol 2015; 265: 8-21.
42. Bennett JL, Lam C, Kalluri SR, et al., Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66: 617-629.
43. Zhang H, Verkman AS,. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 2013; 123: 2306-2316.
44. Hinson SR, Romero MF, Popescu BF, et al., Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109: 1245-1250.
45. Popescu BF, Parisi JE, Cabrera-Gomez JA, et al., Absence of cortical demyelination in neuromyelitis optica. Neurology 2010; 75: 2103-2109.
46. Saadoun S, Papadopoulos MC,. Role of membrane complement regulators in neuromyelitis optica. Mult Scler 2015; 21: 1644-1654.
47. Nicchia GP, Mastrototaro M, Rossi A, et al., Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009; 57: 1363-1373.
48. Green AJ, McQuaid S, Hauser SL, et al., Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 2010; 133 (pt 6): 1591-1601.
49. Seewann A, Kooi EJ, Roosendaal SD, et al., Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012; 78: 302-308.
50. Allen IV, McKeown SR,. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41: 81-91.